Golden Helix, a global leader in bioinformatics solutions for Next-Generation Sequencing (NGS) and precision medicine, is proud to announce a multi-year agreement with all Danish healthcare regions. The agreement aims to enhance the genomic capabilities of multiple laboratories within the regions, supporting critical advancements in cancer and hereditary disease diagnostics.
Health Technology Insights: Archerfish Precision Diagnostics Launches, Advancing Diagnostic Innovation
In a unified effort across Denmark’s healthcare regions, the laboratories are committed to integrating cutting-edge genomic technologies into their clinical workflows to improve patient outcomes. With a longstanding relationship spanning several years, this multi-year agreement solidifies the trust and commitment between Golden Helix and these institutions to drive innovation in genomic medicine.
Mette Christiansen, PhD, Head of the Diagnostic NGS Core Facility, MOMA, Aarhus University Hospital, shared her enthusiasm: “This multi-year agreement with Golden Helix ensures continued access to their advanced technology, which plays a key role in enhancing our diagnostic capabilities and treatment options. We look forward to building on our collaboration with Golden Helix to support improved patient care across Denmark and further advance genomic medicine.”
Health Technology Insights: Linus Health Earns Major Recognition in Medical and Scientific Journals
Andreas Scherer, PhD, President & CEO of Golden Helix, expressed his excitement for the collaboration: “We are honored to strengthen our partnership with the Danish healthcare regions. Their commitment to leveraging advanced genomic technologies aligns perfectly with our mission to empower precision medicine. Together, we are poised to make a lasting impact on the lives of patients across Denmark, delivering tested and proven analytics solutions that drive progress in clinical diagnostics and personalized care.”
Golden Helix’s software solutions are trusted by institutions worldwide, from clinical labs to research organizations, for their ability to streamline genomic data analysis and support scalable, high-quality workflows. This collaboration further underscores Golden Helix’s leadership in empowering healthcare providers with tools to advance precision medicine globally.
Health Technology Insights: Laminar Pharma Shares First PFS Data for LAM561 in Glioblastoma Treatment
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
